Carbohydrate Antigen 125-guided Therapy in Heart Failure

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 360 participants.

Also called NCT02008110

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 360 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02008110
  • EudraCT 2011-000414-20
Other papers using this trial's data
  • Carbohydrate Antigen-125-Guided Therapy in Acute Heart Failure: CHANCE-HF: A Randomized Study JACC. Heart failure, 2016-11 DOI, PubMed 27522630

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Spain (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02008110. Randomized; single masking; primary purpose treatment. Start 2011-12 (registry gives no type); primary completion 2014-07 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Carbohydrate Antigen 125-guided Therapy in Heart Failure
Acronym
CHANCE-HF
Condition
Heart Failure
Intervention (Drug)
CA125 guided strategy
Intervention (Drug)
CA125 guided strategy
Intervention (Drug)
CA125 guided strategy
Intervention (Other)
CA125 guided strategy
Intervention (Drug)
Standard treatment strategy
Intervention (Drug)
CA125 guided strategy
Lead sponsor
Fundación para la Investigación del Hospital Clínico de Valencia (class: other)
Collaborator
Ministerio de Sanidad, Servicios Sociales e Igualdad (class: other government)

Record details

Record id
cardio:ct-nct02008110
Content hash
6d10e4a34f1baf628b60955f96c7127755c509a971b0e9766e9ddad0b7e1412f